Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
41Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03403634CT.gov Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Celecoxib (this asset) | Roswell Park Cancer Institute | P2 | B · 56 |
| Interferon Alfa-2B | Roswell Park Cancer Institute | P2 | B |
| Nedaplatin | Zhejiang Cancer Hospital | P2 | CCC |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | City of Hope Medical Center | P2 | CCC |
| Bms 986156 | M.D. Anderson Cancer Center | P1/2 | CCC |
| Ipilimumab | M.D. Anderson Cancer Center | P1/2 | CCC |
| Durvalumab | City of Hope Medical Center | P1 | CCC |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | City of Hope Medical Center | P1 | CCC |
| Nivolumab | M.D. Anderson Cancer Center | P1/2 | CCC |
+3 more in the Metastatic Carcinoma cohort
Other indications for Celecoxib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis, Hip | — | P4 | BB · 71 |
| Osteoarthritis, Knee | — | P4 | BB · 69 |
| Bipolar Depression | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Interferon Alfa-2BRoswell Park Cancer InstituteB
- NedaplatinZhejiang Cancer HospitalCCC
- Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerCity of Hope Medical CenterCCC
- Bms 986156M.D. Anderson Cancer CenterCCC
- IpilimumabM.D. Anderson Cancer CenterCCC
Citation
Floatz Terminal. Celecoxib in Metastatic Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/celecoxib-metastatic-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →